Addressing Drug Resistance in Cancer: A Team Medicine Approach

• Published in: Journal of clinical medicine 2022-09, Vol.11 (19), p.5701
• Main Authors: Kulkarni, Prakash, Mohanty, Atish, Bhattacharya, Supriyo, Singhal, Sharad, Guo, Linlin, Ramisetty, Sravani, Mirzapoiazova, Tamara, Mambetsariev, Bolot, Mittan, Sandeep, Malhotra, Jyoti, Gupta, Naveen, Kim, Pauline, Babikian, Razmig, Rajurkar, Swapnil, Subbiah, Shanmuga, Tan, Tingting, Nguyen, Danny, Merla, Amartej, Kollimuttathuillam, Sudarsan V, Phillips, Tanyanika, Baik, Peter, Tan, Bradford, Vashi, Pankaj, Shrestha, Sagun, Leach, Benjamin, Garg, Ruchi, Rich, Patricia L, Stewart, F Marc, Pisick, Evan, Salgia, Ravi
• Format: Article
• Language: English
• Subjects: Biology; Cancer therapies; Clinical medicine; Drug dosages; Drug resistance; Epigenetics; Gene expression; Genetic disorders; Genomes; Genotype & phenotype; Medicine; Metastasis; Mutation; Tumors
• ISSN: 2077-0383; 2077-0383
• DOI: 10.3390/jcm11195701

Drug resistance remains one of the major impediments to treating cancer. Although many patients respond well initially, resistance to therapy typically ensues. Several confounding factors appear to contribute to this challenge. Here, we first discuss some of the challenges associated with drug resistance. We then discuss how a 'Team Medicine' approach, involving an interdisciplinary team of basic scientists working together with clinicians, has uncovered new therapeutic strategies. These strategies, referred to as intermittent or 'adaptive' therapy, which are based on eco-evolutionary principles, have met with remarkable success in potentially precluding or delaying the emergence of drug resistance in several cancers. Incorporating such treatment strategies into clinical protocols could potentially enhance the precision of delivering personalized medicine to patients. Furthermore, reaching out to patients in the network of hospitals affiliated with leading academic centers could help them benefit from such innovative treatment options. Finally, lowering the dose of the drug and its frequency (because of intermittent rather than continuous therapy) can also have a significant impact on lowering the toxicity and undesirable side effects of the drugs while lowering the financial burden carried by the patient and insurance providers.